The effects of β-FNA, a highly selective and irreversible μ opioid receptor antagonist, in altering tumor response in A/Jax mice inoculated with S20Y cells were determined. Inoculation of neuroblastoma cells in control subjects resulted in 100% tumor incidence within 16 days, and mean median survival times of 36 and 35 days, respectively, following tumor inoculation. Tumor incidence and survival times were comparable to controls for mice given chronic injections of 2 mg/kg and 10 mg/kg β-FNA every 48 h beginning 2 days after tumor inoculation. Tumor growth was subnormal in the 10 mg/kg β-FNA group. Both dosages of β-FNA were found to block morphine-induced analgesia for 48 h. These results suggests that, in and by themselves, μ receptors selectively antagonized by β-FNA do not play an important role in neuro-oncogenic events.
|Original language||English (US)|
|Number of pages||5|
|Journal||European Journal of Pharmacology|
|State||Published - Oct 8 1985|
Bibliographical noteFunding Information:
This research was supported in part by NIH Grants NS-20623, NS-20500 and NS-01533.
- Endogenous opioids
- Mice Cancer β-Funaltrexamine
- Opioid receptors
- Tumor biology